Approvals· August 10, 2026 · 14 min read
177Lu-Edotreotide (ITM-11) for GEP-NET: COMPETE Phase 3 Data and Lutathera Access
By Ran Chen#Radiolabeled Therapy#Oncology#FDA Approval
Radiopharmaceutical oncology therapies, lutetium-177 peptide receptor radionuclide therapy, COMPETE Phase 3 edotreotide evidence, and HCPCS A-code billing.